Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 377, Issue 9780, 2011, Pages 1846-1854

  Herbst, Roy S ^a,j   Ansari, Rafat ^b   Bustin, Frederique ^c   Flynn, Patrick ^d   Hart, Lowell ^e   Otterson, Gregory A ^f   Vlahovic, Gordana ^g   Soh, Chang Heok ^h   O'Connor, Paula ^h   Hainsworth, John ⁱ  

^a UNIVERSITY OF TEXAS   (United States)

^b Michiana Hematology Oncology   (United States)

^c Centre Hospitalier Regional de La Citadelle   (Belgium)

^d Minnesota Oncology Hematology PA   (United States)

^e Florida Cancer Specialists   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h GENENTECH INC   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j YALE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 79957823572     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60545-X     Document Type: Article

References (33)

1. A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A Jemal, R Siegel, J Xu, E Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. R Pazdur, LR Coia, WJ Hoskins, LD Wagman Cancer management: a multidisciplinary approach 8th edn. 2004 CMP Healthcare Media Manhasset, NY, USA
4. Erlotinib (Tarceva) [package insert] 2007 Genentech South San Francisco, CA, USA
5. FA Shepherd, J Rodrigues Pereira, Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
6. Bevacizumab (Avastin) [package insert] 2007 Genentech South San Francisco, CA, USA
7. A Sandler, R Gray, MC Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
8. DH Johnson, L Fehrenbacher, WF Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191 (Pubitemid 41095154)
9. M Reck, J von Pawel, P Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2010 2415 2422
10. F Ciardiello, R Bianco, V Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
11. RM Shaheen, SA Ahmad, W Liu Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors Br J Cancer 85 2001 584 589 (Pubitemid 32808285)
12. A Bozec, A Sudaka, JL Fischel Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 2008 93 99 (Pubitemid 351920227)
13. N Schicher, V Paulitschke, A Swoboda Erlotinib and bevacizumab have synergistic activity against melanoma Clin Cancer Res 15 2009 3495 3502
14. W Wu, A Onn, T Isobe Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade Mol Cancer Ther 6 2007 471 483 (Pubitemid 46332449)
15. RS Herbst, DH Johnson, E Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
16. RS Herbst, VJ O'Neill, L Fehrenbacher Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 2007 4743 4750 (Pubitemid 350086476)
17. EA Eisenhauer, P Therasse, J Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
18. A Dmitrienko, G Molenberghs, C Chuang-Stein, W Offen Analysis of clinical trials using SAS 2005 SAS Institute Cary, NC, USA
19. PH Westfall, A Krishen Optimally weighted, fixed sequence and gatekeeper multiple testing procedures J Stat Planning Inference 99 2001 25 40 (Pubitemid 33619467)
20. R Brookmeyer, J Crowley A confidence interval for median survival time Biometrics 38 1982 29 41
21. F Ciardiello, R Bianco, R Caputo Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2004 784 793 (Pubitemid 38174017)
22. GN Naumov, MB Nilsson, T Cascone Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 2009 3484 3494
23. RS Herbst, Y Sun, WEE Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
24. RB Natale, D Bodkin, R Govindan Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study J Clin Oncol 27 2009 2523 2529
25. FR Hirsch, M Varella-Garcia, R Dziadziuszko Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer Clin Cancer Res 14 2008 6317 6323
26. NH Andratschke, KH Dittmann, KA Mason Epidermal growth factor receptor as a target to improve treatment of lung cancer Clin Lung Cancer 5 2004 340 352 (Pubitemid 39004331)
27. R Roskoski Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 2004 1 11 (Pubitemid 38670153)
28. TJ Lynch, DW Bell, R Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
29. JG Paez, PA Jänne, JC Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
30. W Pao, V Miller, M Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
31. DA Eberhard, BE Johnson, LC Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
32. VA Miller, GJ Riely, MF Zakowski Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib J Clin Oncol 26 2008 1472 1478
33. VA Miller, P O'Connor, C Soh, F Kabbinavar for the ATLAS Investigators A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 27 2009 LBA8002 (abstr).